All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Multiple Myeloma Hub Co-Chair María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, provided the Multiple Myeloma Hub with updates from this year's virtual American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress. We asked, CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
Significant improvements in both the diagnosis and treatment of MM have been observed in recent years. Despite this, MM remains an incurable disease and patients eventually relapse or become refractory to treatment. CAR T-cell therapy and bispecific T-cell engager monoclonal antibodies have demonstrated promising results in this setting. Here, María-Victoria Mateos outlines the major factors for consideration when choosing a patient's treatment course with such agents.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox